Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer

MLA

Joseph A. Sparano, et al. “Phase II Trial of Saracatinib (AZD0530), an Oral SRC-Inhibitor for the Treatment of Patients with Hormone Receptor-Negative Metastatic Breast Cancer.” Clinical Breast Cancer, vol. 11, no. 5, Jan. 2011. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....17f0dca11076f2bf7adc8d3ed41dcf50&authtype=sso&custid=ns315887.

APA

Joseph A. Sparano, Ayca Gucalp, Christine M. Pellegrino, Chau T. Dang, J. Bromberg, Tiffany A. Traina, Joan Massagué, Jean T. Santamauro, Clifford A. Hudis, Sujata Patil, A. Abbruzzi, James F. Caravelli, Larry Norton, & Maria Theodoulou. (2011). Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. Clinical Breast Cancer, 11(5).

Chicago

Joseph A. Sparano, Ayca Gucalp, Christine M. Pellegrino, Chau T. Dang, J. Bromberg, Tiffany A. Traina, Joan Massagué, et al. 2011. “Phase II Trial of Saracatinib (AZD0530), an Oral SRC-Inhibitor for the Treatment of Patients with Hormone Receptor-Negative Metastatic Breast Cancer.” Clinical Breast Cancer 11 (5). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....17f0dca11076f2bf7adc8d3ed41dcf50&authtype=sso&custid=ns315887.